Source-grounded facts extracted from Forte Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2026-05-29 meeting.
“4. Approval of the Amended and Restated 2021 Equity Incentive Plan . The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,911,879 3,997,050 351,042 1,506,063”
Forte Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.
“3. Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,143,153 3,764,729 352,089 1,506,063”
Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 17,722,893 3,182 39,959 0”
Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2026-05-29 meeting.
“1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Steven Kornfeld 12,286,043 3,973,928 1,506,063 Scott Brun, M.D. 12,958,889 3,301,082 1,506,063 Paul A. Wagner, Ph.D. 16,027,110 232,861 1,506,063”
Forte Biosciences, Inc. entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $150 million (effective 2026-04-08).
“On April 8, 2026, Forte Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 5,709,936 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $26.27 per share (the “Shares”).”
Forte Biosciences, Inc. reported the year ended December 31, 2025 results: net income $(69,375) thousand, EPS $(4.71).
“Interest income 2,715 1,314 Other expense, net (396 ) (190 ) Total other income, net 2,319 1,124 Net loss before taxes (68,338 ) (35,478 ) Income tax expense 1,037 — Net loss $ (69,375 ) $ (35,478 ) Per share information: Net loss per share - basic and diluted $ (4.71 ) $ (12.17 ) Weighted average share, and pre-funded warrants outstanding, basic and diluted”
Shiv Kapoor was appointed as Director at Forte Biosciences, Inc..
“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”
Richard Vincent was appointed as Director at Forte Biosciences, Inc..
“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”
Lawrence Eichenfield resigned as Director at Forte Biosciences, Inc..
“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”
Donald A. Williams resigned as Director at Forte Biosciences, Inc..
“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”
Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).
“On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.”
Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income $ (31,476 ), EPS $ (1.00 ).
“On March 18, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.